AZD0120

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaMultiple SclerosisKidney TransplantAL AmyloidosisRelapsed/refractory Multiple MyelomaNewly Diagnosed Multiple MyelomaLupus Erythematosus, SystemicCytopenia

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

Venclexta

AbbVie

Phase 3

172

Keytruda

Merck & Co.

Phase 3

173

Opdivo

Bristol-Myers Squibb

Phase 3

114

Treanda

AAzurity Pharmaceuticals

Phase 3

195

Neulasta

Amgen

Phase 3

56

Cytosar

Teva

Phase 3

47

Busulfex

Akero Therapeutics

Phase 3

148

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

99

Sylvant

RRECORDATI GROUP

Phase 3

810

Linvoseltamab

Regeneron

Phase 3

9Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Newly Diagnosed Multiple Myeloma2 trials

A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)

Recruiting·AstraZeneca·Phase 3·NCT07735637·750 enrolled

Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)

Recruiting·AstraZeneca·Phase 3·NCT07764978·750 enrolled

Multiple Myeloma2 trials

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

Recruiting·AstraZeneca·Phase 3·NCT07391657·508 enrolled

A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)

Recruiting·AstraZeneca·Phase 1·NCT07073547·40 enrolled

Kidney Transplant1 trial

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

Not yet recruiting·TTongji Hospital·Phase 1·NCT07350837·12 enrolled

Systemic Sclerosis1 trial

A Phase 1b/2, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

Recruiting·AstraZeneca·Preclinical·NCT07295847·27 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Recruiting·AstraZeneca·Preclinical·NCT05850234·232 enrolled

4 more indications

Lupus Erythematosus, Systemic1 trial

A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)

Recruiting·AstraZeneca·Preclinical·NCT06897930·150 enrolled

Cytopenia1 trial

A Phase 1, Open-Label, Single Center Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen (BCMA), in Subjects With Relapsed and Refractory Persistent Autoimmune Cytopenia

Not yet recruiting·SSaurabh Dahiya·Phase 1·NCT07790575·16 enrolled

Multiple Sclerosis1 trial

A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis

Recruiting·AstraZeneca·Phase 1·NCT07224373·24 enrolled

AL amyloidosis1 trial

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Recruiting·AstraZeneca·Preclinical·NCT07081646·91 enrolled

Details

Drug Info

Related News